2月26日 - ** 制药商联合治疗UTHR.O股价盘前下跌3.5%，报345美元
** 根据LSEG汇编的数据，该公司在 (link)，每股季度利润为6.19美元，低于分析师预计的每股6.31美元。
** 然而，由于肺部疾病吸入药物 Tyvaso 的销售，该公司第四季度营收达到 7.359 亿美元，略高于预期的 7.347 亿美元。
** 经纪公司 Leerink Partners 称，与一年前不同的是，Tyvaso 似乎无法在本季度逆季节性趋势而动。
** 该股在过去 12 个月中上涨了约 60
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.